Dr. Qingyan Sandy Au is Director of Multiplexing at NeoGenomics. In this role, she is responsible for overall scientific and operational function of Multiplexing modality including MultiOmyx™, Vectra Polaris™ and RareCyte CTC technology platforms. She has over 15 years of experience in multiplexed immunofluorescence assay development & validation in cell and tissue-based assays in support of exploratory, translational and clinical research studies. Sandy earned her PhD in Biomedical Sciences from the University of California at Riverside, and she also holds Master’s degree in Genetics from Fudan University.